Executive Series interview:
Tom Piotrowski: ”So when you look out over the next six months, what are going to be the important milestones for Starpharma?”
Jackie Fairley: “On the DEP side of things, completion of our Phase 2 trial for Dep-Docetaxel.”
*This interview is freely available on YouTube and on Hotcopper post #34314084
**Direct quotes. Word for word.
***Unfortunately for SPL shareholders, this interview was conducted in July 2018.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $54.36M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $53.97K | 420.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70507 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 493895 | 3 |
View Market Depth
| Last trade - 15.14pm 19/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |